purpose of review to assess the effectiveness of drug and nondrug therapies for treating acute mania or depression symptoms and preventing relapse in adults with bipolar disorder (bd) diagnoses, including bipolar i disorder (bd-i), bipolar ii disorder (bd-ii), and other types. key messages acute mania treatment: lithium, asenapine, cariprazine, olanzapine, quetiapine, risperidone, and ziprasidone may modestly improve acute mania symptoms in adults with bd-i.
we generate breakthrough discoveries that advance scientific understanding and lead to new interventions for preventing and treating bipolar disorder.
what is new in research on bipolar disorder?
the dauten family center for bipolar treatment innovation at mass general is dedicated to finding new treatments for bipolar disorder, providing high-quality clinical care and educating our colleagues, our patients, their families and the community about this disorder.
learn how bipolar disorder treatment, including medication, therapy, and lifestyle changes, can help you manage symptoms and improve your quality of life.
background in mental health care, clinical practice is often based on the best available research evidence. however, research findings are difficult to apply to clinical practice, resulting in an implementation gap. to bridge the gap between research and clinical practice, patients’ perspectives should be used in health care and research. this study aimed to understand the challenges people with bipolar disorder (bd) experience and examine what these challenges imply for health care and research needs. methods two qualitative studies were used, one to formulate research needs and another to formulate healthcare needs. in both studies focus group discussions were conducted with patients to explore their challenges in living with bd and associated needs, focusing on the themes diagnosis, treatment and recovery. results patients’ needs are clustered in ‘disorder-specific’ and ‘generic’ needs. specific needs concern preventing late or incorrect diagnosis, support in search for individualized treatment and supporting clinical, functional, social and personal recovery. generic needs concern health professionals, communication and the healthcare system. conclusion patients with bd address disorder-specific and generic healthcare and research needs. this indicates that disorder-specific treatment guidelines address only in part the needs of patients in everyday clinical practice.
for people with bipolar disorder, a new way to measure the impact of treatment may be to measure the size of the “spikes” in their measures of mood and mania
new research is helping practitioners better understand the symptoms of pediatric bipolar disorder.
bipolar disorder is a mood disorder that can cause intense mood swings. it's also called manic depression. learn about the types, symptoms, treatment, and more.
the mood and anxiety disorders treatment and research program at the university of pennsylvania strives to provide the best in cutting-edge treatment for psychiatric illness.
introduction bipolar disorder is a chronic and complex disorder that can be difficult to treat. the objective of this retrospective study was to describe treatment patterns among patients with bipolar disorder. methods adults newly diagnosed with bipolar disorder from 2016 to 2018 were identified using the ibm® marketscan® commercial claims database. patients were enrolled for at least 12 months prior to and 6 months after initial diagnosis. lines of therapy (lots) were continuous treatment periods based on filled prescriptions; medications, such as antidepressants, mood stabilizers, atypical antipsychotics, benzodiazepines, stimulants, and off-label prescriptions, were recorded. all data were analyzed descriptively. results a total of 40,345 patients met criteria. the most common initial episode types were bipolar ii (38.1%), and bipolar i depression (29.8%), mania (12.8%), and mixed features (12.0%). among all episode types, approximately 90% of patients received treatment (lot1) and approximately 80% of these patients received at least one additional lot. across all episode types, the most common medication classes in lot1 (n = 36,587) were mood stabilizers (43.8%), antidepressants (42.3%; 12.9% as monotherapy), atypical antipsychotics (31.7%), and benzodiazepines (20.7%); with subsequent lots, antidepressant (51.4–53.8%) and benzodiazepine (26.9–27.4%) usage increased. also in lot1, there were 2067 different regimens. treatment patterns were generally similar across episode type. conclusions antidepressants and benzodiazepines were frequently prescribed to treat bipolar disorder despite guidelines recommending against use as frontline therapy. these results highlight the considerable heterogeneity in care and suggest that many clinicians treating bipolar disorder are not using evidence-based prescribing practices.
patients from across the country will be recruited to take part in a major trial examining a new treatment for bipolar disorder.
bipolar disorder is a mental illness characterized by extreme mood swings, including episodes of mania and depression. these mood swings can affect a person
background bipolar disorder is a common psychiatric disorder with a massive psychological and social burden. research indicates that treatment adherence is not good in these patients. the families’ knowledge about the disorder is fundamental for managing their patients’ disorder. the purpose of the present study was to investigate the knowledge of the family members of a sample of iranian patients with bipolar i disorder (bd-i) and to explore the potential reasons for treatment non-adherence. methods this study was conducted by qualitative content analysis. in-depth interviews were held and open-coding inductive analysis was performed. a thematic content analysis was used for the qualitative data analysis. results the viewpoints of the family members of the patients were categorized in five themes, including knowledge about the disorder, information about the medications, information about the treatment and the respective role of the family, reasons for pharmacological treatment non-adherence, and strategies applied by families to enhance treatment adherence in the patients. the research findings showed that the family members did not have enough information about the nature of bd-i, which they attributed to their lack of training on the disorder. the families did not know what caused the recurrence of the disorder and did not have sufficient knowledge about its prescribed medications and treatments. also, most families did not know about the etiology of the disorder. conclusion the lack of knowledge among the family members of patients with bd-i can have a significant impact on relapse and treatment non-adherence. these issues need to be further emphasized in the training of patients’ families. the present findings can be used to re-design the guidelines and protocols in a way to improve treatment adherence and avoid the relapse of bd-i symptoms.
engaging people with bipolar disorder and translating their experiences into scientific research will help move from hope to real improvements in treatment.
other mental illness diagnoses, taking psychotropic medication (prescribed to treat those illnesses, and specific health service use patterns are strong indicators of bipolar disorder, show researchers from the university of manchester and keele university. the findings – published in the british journal of general practice – will enable do...
bipolar disorder is a serious mental health condition that affects more than 40 million people worldwide. while bipolar disorder research has historically been underfunded, three family philanthropies recently announced they are donating $150 million to launch a new initiative known as bd2: breakthr
living with bipolar disorder comes with various challenges for both you and your loved ones. these organizations and websites offer information and support.
a study covering the 20 years between 1997 and 2016 shows that substantial changes have occurred in the way doctors are treating outpatients diagnosed with bipolar disorder. among a number of important changes, one in particular stands out: a much smaller fraction of outpatients today are being treated with a mood stabilizer and a greater fraction are being treated with a second-generation antipsychotic medication.
bipolar disorders (bds) are recurrent and sometimes chronic disorders of mood that affect around 2% of the world’s population and encompass a spectrum between severe elevated and excitable mood states (mania) to the dysphoria, low energy, and despondency of depressive episodes. the illness commonly starts in young adults and is a leading cause of disability and premature mortality. the clinical manifestations of bipolar disorder can be markedly varied between and within individuals across their lifespan. early diagnosis is challenging and misdiagnoses are frequent, potentially resulting in missed early intervention and increasing the risk of iatrogenic harm. over 15 approved treatments exist for the various phases of bipolar disorder, but outcomes are often suboptimal owing to insufficient efficacy, side effects, or lack of availability. lithium, the first approved treatment for bipolar disorder, continues to be the most effective drug overall, although full remission is only seen in a subset of patients. newer atypical antipsychotics are increasingly being found to be effective in the treatment of bipolar depression; however, their long term tolerability and safety are uncertain. for many with bipolar disorder, combination therapy and adjunctive psychotherapy might be necessary to treat symptoms across different phases of illness. several classes of medications exist for treating bipolar disorder but predicting which medication is likely to be most effective or tolerable is not yet possible. as pathophysiological insights into the causes of bipolar disorders are revealed, a new era of targeted treatments aimed at causal mechanisms, be they pharmacological or psychosocial, will hopefully be developed. for the time being, however, clinical judgment, shared decision making, and empirical follow-up remain essential elements of clinical care. this review provides an overview of the clinical features, diagnostic subtypes, and major treatment modalities available to treat people with bipolar disorder, highlighting recent advances and ongoing therapeutic challenges.
bipolar disorder is a medical condition characterized by extreme mood swings that affect how people think, behave and function.
new research from the universities of keele and manchester has found that psychiatric diagnoses, psychotropic prescriptions, and health service use patterns are strong indicators of bipolar disorder.
faculty members david bond, md, phd; and piper meyer-kalos, phd, lp; are basing the blueprint on an existing model, hoping to fill current diagnosis/treatment gaps.
bipolar disorder is a brain disorder that includes extreme mood shifts. learn about symptoms and treatment.
who fact sheet on bipolar disorder, including key facts, symptoms and patterns, risks and protective factors, treatment and care, and who response.
how psychologists’ understanding of bipolar disorder has changed over the past 3 decades and how those changes have led to earlier and more accurate diagnosis and increasingly personalized treatments.
backgroundbipolar disorder (bd) is predominantly treated with psychotropic drugs, but bd is a complex medical condition and the contribution of psychotropic ...
this literature review focuses on randomized controlled trials of psychotherapy for bipolar disorder. evidence-based psychotherapies are shown to play an important role in the development of skills needed to manage the persistent and lifelong consequences of bipolar disorder.
find out about bipolar disorder, including symptoms, how it's diagnosed and treatments.
the pandemic increased our collective focus on mental health, driving research into conditions such as bipolar disorder.
va hsr&d research topics
bipolar ii disorder is characterised by a pattern of depressive episodes and hypomanic episodes, which are less severe than full-blown mania.
1- atypical antipsychotics for continuation and maintenance treatment after an acute manic episode team serge beaulieu, md, phd, mario roy, md, abdallah dallal, md, mario roy, md, joseph thavundayil, md, ... read more
new treatments for bipolar disorder are on the horizon. here’s a look at some of the latest advances, as well as experimental therapies.
learn about nimh research on bipolar disorder. find resources on the signs and symptoms of bipolar disorder, types, and potential treatments and therapies.
learn about bipolar disorder, including types, symptoms, and treatment options
bipolar disorder news. read the latest medical research on causes, symptoms and new treatments for bipolar disorder.
background and objectives for the systematic review bipolar disorder is a serious mental illness.